Please login to the form below

Not currently logged in
Email:
Password:

MSD invests in FKD Therapies

MSD has taken an equity stake in the Finland based company, FKD Therapies, owned by former CEO of Ark Therapeutics Nigel Parker

MSD (known as Merck in the US and Canada) has taken an equity stake in the Finland based company, FKD Therapies. FKD Therapies, which has reserves of $16m, is a company started by Nigel Parker, the former chief executive of Ark Therapeutics.

This investment by MSD constitutes part of a deal that will see FKD Therapies develop MSD's gene therapy portfolio, which includes a possible treatment for bladder cancer.

The possible bladder treatment that FKD Therapies will be developing contains an adenovirus, which is designed to carry an interferon gene into the bladder wall cells. Here, it expresses a protein within the bladder, possibly increasing its ability to penetrate tumour cells.

MSD's gene therapy programmes for glaucoma surgery failure and the treatment of solid tumours were also available to develop.

20th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...
How Helpful are Simple Health Messages?
...

Infographics